Medulloblastoma drugs in development: Current leads, trials and drawbacks

Area of Science:

• Pediatric oncology
• Neuro-oncology
• Molecular targeted therapy

Background:

• Medulloblastoma (MB) is the most frequent malignant pediatric brain tumor.
• Current treatments (surgery, radiation, chemotherapy) have limitations, with a significant rate of relapse and poor prognosis.
• MB is classified into four distinct molecular groups: Wnt, Hh, Group 3, and Group 4.

Purpose of the Study:

• To review recent advancements in targeted chemotherapies for medulloblastoma.
• To cover progress across all molecular subtypes of MB.
• To discuss the advantages of targeted therapies over traditional treatments.

Main Methods:

• Literature review of recent studies on targeted therapies for medulloblastoma.
• Analysis of clinical and molecular classifications of MB.
• Synthesis of data on efficacy and toxicity of targeted agents.

Main Results:

• Targeted therapies are increasingly developed for MB, leveraging a better understanding of disrupted molecular pathways.
• These therapies demonstrate improved efficacy and reduced toxicity compared to conventional chemotherapy.
• Several targeted drugs are approved and utilized in clinical practice for MB treatment.

Conclusions:

• Targeted chemotherapy represents a promising approach for managing medulloblastoma.
• Continued research into targeted agents is crucial for improving outcomes in all MB subtypes.
• Personalized treatment strategies based on molecular classification are key to overcoming MB recurrence.